Skip to main content
OpenTrials
Completed

NCT Number: NCT07178197

Sarcopenia in Patients With Idiopathic Pulmonary Fibrosis

Sarcopenia negatively affects the prognosis of chronic diseases. However, the importance of sarcopenia in patients with idiopathic pulmonary fibrosis (IPF) has been less emphasized. The aim of the study is to determine the prevalence of sarcopenia in patients with IPF and to evaluate the impact of sarcopenia on quality of life and disease progression.

This study was designed as a descriptive cross-sectional. The study included patients diagnosed with IPF. Hand dynamometry and bioelectrical impedance analysis (BIA) were used to for diagnose of sarcopenia. Pulmonary function tests, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) measurements were examined. The 6-minute walk distance (6MWD) and 4-meter walking speed were recorded. The St. George Respiratory Questionnaire (SGRQ) was used to assess quality of life. All patients were evaluated for progressive disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Idiopathic Pulmonary Fibrosis (IPF) Atrophy Idiopathic Pulmonary Fibrosis Lung Diseases Lung Diseases, Interstitial Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Pulmonary Fibrosis Respiratory Tract Diseases Sarcopenia Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mersin University Faculty of Medicine

Mersin, Turkey (Türkiye)

About this study

The study was designed as a cross-sectional study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Being over 18 years of age
  • Signing the informed consent form
  • Having a diagnosis of IPF for at least one month

Exclusion criteria

  • Pregnancy
  • History of cancer within the last 5 years
  • History of lung surgery
  • History of neuromuscular disease
  • Active pulmonary tuberculosis
  • Active respiratory tract infection
  • Inability to perform pulmonary function tests
  • Presence of a pacemaker
  • History of systemic steroid use within the past 3 months
  • Inability to use a hand dynamometer

Treatment and study plan

Primary outcomes

  1. Hand Grip Strength

    Time frame: through study completion, an average of 1 year

    Hand Grip Strength (kg)- Grip strength measurement using a hand dynamometer

  2. SMI (skeletal muscle mass index)

    Time frame: through study completion, an average of 1 year

    SMI (skeletal muscle mass index) (kg/m2) - SMI measurement using the Bioelectrical Impedance Analysis (BIA) device

  3. Forced Expiratory Volume in 1 second (FEV1)

    Time frame: through study completion, an average of 1 year

    Measurement of FEV1 for the assessment of pulmonary function

  4. Forced Vital Capacity (FVC)

    Time frame: through study completion, an average of 1 year

    Measurement of FVC for the assessment of pulmonary function

  5. Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO)

    Time frame: through study completion, an average of 1 year

    Measurement of DLCO for the assessment of pulmonary function.

  6. Total Lung Capacity (TLC)

    Time frame: through study completion, an average of 1 year

    Measurement of TLC for the assessment of pulmonary function.

  7. Respiratory Muscle Strength

    Time frame: through study completion, an average of 1 year

    Measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) for assessment of respiratory muscle strength

  8. Six Minute Walk Test (6MWT)

    Time frame: through study completion, an average of 1 year

    Distance walked in six minutes (m)

  9. Gait speed

    Time frame: through study completion, an average of 1 year

    4-meter walking speed (m/s)

  10. St. George's Respiratory Questionnaire (SGRQ)

    Time frame: through study completion, an average of 1 year

    The questionnaire is designed to measure quality of life. It consists of symptom, activity, impact, and total scores. Each score ranges from 0 to 100. High scores indicate lower quality of life.

  11. Progressive Disease

    Time frame: through study completion, an average of 1 year

    Examination of all participants from clinical, physiological, and radiological perspectives

Secondary outcomes

  1. Body Mass Index ( BMI)

    Time frame: through study completion, an average of 1 year

    kg/m2

Sponsors and collaborators

Lead sponsor

Mersin University

Other

Registry information

Official study title

Association of Sarcopenia With Quality of Life and Progression of Disease in Patients With Idiopathic Pulmonary Fibrosis

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Sep 17, 2025
Registry last updated
Sep 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.